FDA Approved Indications for this Orphan Drug:

Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib

FDA Marketing Approval issued as of:

Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
Genentech, Inc.

FDA Designation Date:

FDA Drug Designation:
Treatment of ALK-positive non-small cell lung cancer